Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz [PDF]
, 2018 Efavirenz is a potent antiretroviral agent used in combination with other antiretroviral agents as part of highly activeantiretroviral therapy. Efavirenz is generally well tolerated because the majority of its adverse effects are self-limiting,with ...
Walmsley, Sharon +4 more
core +4 more sources
Effect of Efavirenz on UDP-Glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 Activities in Human Liver Microsomes [PDF]
Molecules, 2012 Efavirenz is a non-nucleoside reverse transcriptase inhibitor used for the treatment of human immunodeficiency virus type 1 infections. Drug interactions of efavirenz have been reported due to in vitro inhibition of CYP2C9, CYP2C19, CYP3A4, and UDP ...
Hye Suk Lee +4 more
doaj +2 more sources
CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease [PDF]
Alzheimer’s Research & Therapy, 2022 Background Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC).
Alan J. Lerner +12 more
doaj +2 more sources
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid
Southern African Journal of HIV MedicineBackground: CYP2B6 slow metabolisers have higher efavirenz concentrations, which are further increased by isoniazid inhibiting efavirenz’s accessory metabolic pathway.
Jessica Taylor +6 more
doaj +3 more sources
The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. [PDF]
Clin Transl SciABSTRACT Quizartinib is an oral, potent, selective FMS‐like tyrosine kinase 3 (FLT3) inhibitor, approved for the treatment of FLT3‐internal tandem duplication (ITD)–positive acute myeloid leukemia (AML) and under investigation in patients with newly diagnosed FLT3‐ITD–negative AML.
Yoo Y +8 more
europepmc +2 more sources
Frontiers in Pharmacology, 2020 Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for ...
Sabina Mugusi +11 more
doaj +1 more source
Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz
Biomedicines, 2022 Drug-induced liver injury (DILI) constitutes a clinical challenge due to the incomplete characterization of the mechanisms involved and potential risk factors.
Fernando Alegre +9 more
doaj +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice [PDF]
Iranian Journal of Basic Medical Sciences, 2020 Objective(s): Efavirenz, has proven to be effective in suppressing human immunodeficiency virus (HIV) viral load; however, complaints of sleep disorders including hallucination, and insomnia have greatly contributed to non-adherence to antiretroviral ...
Olufunke Dosumu +3 more
doaj +1 more source
Frontiers in Neurology, 2019 Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz may be at risk of toxicity.
Charles K. Hammond +4 more
doaj +1 more source